News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,017 Results
Type
Article (18896)
Company Profile (102)
Press Release (311019)
Section
Business (89101)
Career Advice (1319)
Deals (17482)
Drug Delivery (59)
Drug Development (61153)
Employer Resources (60)
FDA (9068)
Job Trends (7483)
News (174114)
Policy (15208)
Tag
Academia (1199)
Alliances (17719)
Alzheimer's disease (861)
Approvals (9063)
Artificial intelligence (90)
Bankruptcy (137)
Best Places to Work (6351)
Biotechnology (67)
Breast cancer (195)
Cancer (1227)
Cardiovascular disease (89)
Career advice (1034)
CAR-T (65)
Cell therapy (191)
Clinical research (50586)
Collaboration (313)
Compensation (130)
COVID-19 (2180)
Data (1268)
Diabetes (174)
Diagnostics (3263)
Earnings (52179)
Events (52495)
Executive appointments (173)
FDA (9618)
Funding (313)
Gene therapy (131)
GLP-1 (585)
Government (2371)
Healthcare (9637)
Infectious disease (2228)
Inflammatory bowel disease (75)
Interviews (241)
IPO (10117)
Job creations (1450)
Job search strategy (906)
Layoffs (210)
Legal (2459)
Lung cancer (190)
Lymphoma (85)
Manufacturing (108)
Medical device (6302)
Medtech (6302)
Mergers & acquisitions (7575)
Metabolic disorders (453)
Neuroscience (1130)
NextGen: Class of 2025 (2658)
Non-profit (1842)
Northern California (1209)
Obesity (267)
Opinion (91)
Parkinson's disease (82)
People (15346)
Phase I (14322)
Phase II (24980)
Phase III (16262)
Pipeline (545)
Postmarket research (1586)
Preclinical (4745)
Radiopharmaceuticals (146)
Rare diseases (194)
Real estate (1733)
Regulatory (11462)
Research institute (1157)
Resumes & cover letters (257)
Southern California (1068)
Startups (1337)
United States (10008)
Vaccines (425)
Weight loss (191)
Date
Today (54)
Last 7 days (382)
Last 30 days (1443)
Last 365 days (21977)
2025 (1399)
2024 (22031)
2023 (24445)
2022 (29984)
2021 (32062)
2020 (30536)
2019 (22703)
2018 (17293)
2017 (17516)
2016 (15308)
2015 (18682)
2014 (13373)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (406)
Asia (21461)
Australia (3859)
California (2716)
Canada (972)
China (267)
Colorado (99)
Connecticut (131)
Delaware (71)
Europe (47616)
Florida (337)
Georgia (107)
Illinois (173)
Indiana (148)
Japan (79)
Maryland (391)
Massachusetts (2022)
Michigan (81)
Minnesota (148)
New Jersey (806)
New York (809)
North Carolina (385)
Northern California (1209)
Ohio (77)
Pennsylvania (596)
South America (567)
Southern California (1068)
Texas (395)
Utah (72)
Washington State (251)
330,017 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Colorado’s Life Sciences Ecosystem Raised $2.15 Billion in 2024
Fundraising Exceeds $2B for the Second Time in Four-Year Period
December 19, 2024
·
1 min read
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Legal
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.
October 10, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Androgenetic Alopecia Market Size to reach USD 2,823.2 Million by 2035, Impelled by Development of Personalized Treatments
January 23, 2025
·
13 min read
Press Releases
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
January 27, 2025
·
19 min read
Press Releases
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 million Management to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024
November 7, 2024
·
23 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
January 27, 2025
·
19 min read
Press Releases
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
December 18, 2024
·
5 min read
Press Releases
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
December 31, 2024
·
6 min read
Press Releases
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
December 6, 2024
·
6 min read
1 of 33,002
Next
